Skip to main content
Top
Published in: Clinical and Translational Oncology 10/2018

Open Access 01-10-2018 | Research Article

Long-term crude probabilities of death among breast cancer patients by age and stage: a population-based survival study in Northeastern Spain (Girona–Tarragona 1985–2004)

Authors: R. Clèries, A. Ameijide, M. Buxó, J. M. Martínez, R. Marcos-Gragera, M.-L. Vilardell, M. Carulla, Y. Yasui, M. Vilardell, J. A. Espinàs, J. M. Borràs, J. Galceran, À. Izquierdo

Published in: Clinical and Translational Oncology | Issue 10/2018

Login to get access

Abstract

Background

We provide population-based long-term survival indicators of breast cancer patients by quantifying the observed survival, and the probabilities of death due to breast cancer and to other causes by age and tumor stage at diagnosis.

Methods

We included a total of 10,195 female patients diagnosed before 85 years with invasive primary breast cancer in Girona and Tarragona during the periods 1985–1994 and 1995–2004 and followed-up until December 31st 2014. The survival indicators were estimated at 5, 10, 15 and 20 years of follow-up comparing diagnostic periods.

Results

Comparing diagnostic periods: I) the probability of death due to other causes did not change; II) the 20-year survival for women diagnosed ≤ 49 years increased 13% (1995–2004 = 68%; 1985–1994:55%), whereas their probability of death due to breast cancer decreased at the same pace (1995–2004 = 29%; 1985–1994 = 42%); III) at 10 years of follow-up, decreases in the probabilities of death due to breast cancer across age groups switched from 11 to 17% resulting in a risk of death reduction of 19% after adjusting by stage. During 1995–2004, the stage-specific 10-year probabilities of death due to breast cancer switched from: 3–6% in stage I, 18–20% in stage II, 34–46% in stage III and surpassed 70% in stage IV beyond 5 years after diagnosis.

Conclusions

In our study, women diagnosed with breast cancer had higher long-term probability to die from breast cancer than from other causes. The improvements in treatment and the lead-time bias in detecting cancer in an early stage resulted in a reduction of 19% in the risk of death between diagnostic periods.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.CrossRef Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.CrossRef
2.
go back to reference Galceran J, Ameijide A, Carulla M, Mateos A, Quirós JR, Rojas D, et al. Cancer incidence in Spain, 2015. Clin Transl Oncol. 2017;19(7):799–825.CrossRef Galceran J, Ameijide A, Carulla M, Mateos A, Quirós JR, Rojas D, et al. Cancer incidence in Spain, 2015. Clin Transl Oncol. 2017;19(7):799–825.CrossRef
3.
go back to reference Clèries R, Ameijide A, Marcos-Gragera R, Pareja L, Carulla M, Vilardell ML, Esteban L, Buxó M, Espinàs JA, Puigdefàbregas A, Ribes J, Izquierdo A, Galceran J, Borrás JM. Predicting the cancer burden in Catalonia between 2015 and 2025: the challenge of cancer management in the elderly. Clin Transl Oncol. 2017. https://doi.org/10.1007/s12094-017-1764-5.CrossRefPubMed Clèries R, Ameijide A, Marcos-Gragera R, Pareja L, Carulla M, Vilardell ML, Esteban L, Buxó M, Espinàs JA, Puigdefàbregas A, Ribes J, Izquierdo A, Galceran J, Borrás JM. Predicting the cancer burden in Catalonia between 2015 and 2025: the challenge of cancer management in the elderly. Clin Transl Oncol. 2017. https://​doi.​org/​10.​1007/​s12094-017-1764-5.CrossRefPubMed
4.
go back to reference Pollán M, Pastor-Barriuso R, Ardanaz E, Argüelles M, Martos C, Galcerán J, et al. Recent changes in breast cancer incidence in Spain, 1980-2004. J Natl Cancer Inst. 2009;101:1584–91.CrossRef Pollán M, Pastor-Barriuso R, Ardanaz E, Argüelles M, Martos C, Galcerán J, et al. Recent changes in breast cancer incidence in Spain, 1980-2004. J Natl Cancer Inst. 2009;101:1584–91.CrossRef
5.
go back to reference Galceran J, Puigdefàbregas A, Ribas G, Izquierdo A, Pareja L, Marcos-Gragera R. Evolución de la supervivencia del cáncer en Cataluña y comparación con Europa. Med Clin. 2008;131:19–24.CrossRef Galceran J, Puigdefàbregas A, Ribas G, Izquierdo A, Pareja L, Marcos-Gragera R. Evolución de la supervivencia del cáncer en Cataluña y comparación con Europa. Med Clin. 2008;131:19–24.CrossRef
6.
go back to reference Chirlaque MD, Salmerón D, Galceran J, Ameijide A, Mateos A, Torrella A, Jiménez R, Larrañaga N, Marcos-Gragera R, Ardanaz E, Sant M, Minicozzi P, Navarro C, Sánchez MJ; REDECAN Working Group. Cancer survival in adult patients in Spain. Results from nine population-based cancer registries. Clin Transl Oncol. 2018;20(2):201–11.CrossRef Chirlaque MD, Salmerón D, Galceran J, Ameijide A, Mateos A, Torrella A, Jiménez R, Larrañaga N, Marcos-Gragera R, Ardanaz E, Sant M, Minicozzi P, Navarro C, Sánchez MJ; REDECAN Working Group. Cancer survival in adult patients in Spain. Results from nine population-based cancer registries. Clin Transl Oncol. 2018;20(2):201–11.CrossRef
7.
go back to reference Clèries R, Buxó M, Yasui Y, Marcos-Gragera R, Martínez JM, Ameijide A, et al. Estimating long-term crude probability of death among young breast cancer patients: a Bayesian approach. Tumori. 2016;102:555–61.CrossRef Clèries R, Buxó M, Yasui Y, Marcos-Gragera R, Martínez JM, Ameijide A, et al. Estimating long-term crude probability of death among young breast cancer patients: a Bayesian approach. Tumori. 2016;102:555–61.CrossRef
8.
go back to reference Croccetti E, Roche L, Buzzoni C, di Costanzo F, Molinié F, Caldarelle A, et al. Trends in net survival from breast cancer in six European Latin countries: results from the SUDCAN population-based study. Eur J Cancer Prev. 2017;26:S85–91.CrossRef Croccetti E, Roche L, Buzzoni C, di Costanzo F, Molinié F, Caldarelle A, et al. Trends in net survival from breast cancer in six European Latin countries: results from the SUDCAN population-based study. Eur J Cancer Prev. 2017;26:S85–91.CrossRef
9.
go back to reference Clèries R, Martínez JM, Moreno V, Yasui Y, Ribes J, Borràs JM. Predicting the change in breast cancer deaths in Spain by 2019: a Bayesian approach. Epidemiology. 2013;24:454–60.CrossRef Clèries R, Martínez JM, Moreno V, Yasui Y, Ribes J, Borràs JM. Predicting the change in breast cancer deaths in Spain by 2019: a Bayesian approach. Epidemiology. 2013;24:454–60.CrossRef
10.
go back to reference Allemani C, Minicozzi P, Berrino F, Bastiaannet E, Gavin A, Galceran J, et al. Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000–2002. Int J Cancer. 2013;132:2404–12.CrossRef Allemani C, Minicozzi P, Berrino F, Bastiaannet E, Gavin A, Galceran J, et al. Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000–2002. Int J Cancer. 2013;132:2404–12.CrossRef
11.
go back to reference Chirlaque MD, Salmerón D, Ardanaz E, Galceran J, Martínez R, Marcos-Gragera R, et al. Cancer survival in Spain: estimate for nine major cancers. Ann Oncol. 2010;21(Suppl 3):iii21–9.PubMed Chirlaque MD, Salmerón D, Ardanaz E, Galceran J, Martínez R, Marcos-Gragera R, et al. Cancer survival in Spain: estimate for nine major cancers. Ann Oncol. 2010;21(Suppl 3):iii21–9.PubMed
12.
go back to reference Brenner H, Hakulinen T. Are patients diagnosed with breast cancer before age 50 years ever cured? J Clin Oncol. 2004;22:432–8.CrossRef Brenner H, Hakulinen T. Are patients diagnosed with breast cancer before age 50 years ever cured? J Clin Oncol. 2004;22:432–8.CrossRef
13.
go back to reference Louwman WJ, Klokman WJ, Coebergh JWW. Excess mortality from breast cancer 20 years after diagnosis when life expectancy is normal. Br J Cancer. 2001;84:700–3.CrossRef Louwman WJ, Klokman WJ, Coebergh JWW. Excess mortality from breast cancer 20 years after diagnosis when life expectancy is normal. Br J Cancer. 2001;84:700–3.CrossRef
14.
go back to reference Woods LM, Rachet B, Lambert PC, Coleman MP. “Cure” from breast cancer among two populations of women followed for 23 years after diagnosis 2009. Ann Oncol. 2009;20(8):1331–6.CrossRef Woods LM, Rachet B, Lambert PC, Coleman MP. “Cure” from breast cancer among two populations of women followed for 23 years after diagnosis 2009. Ann Oncol. 2009;20(8):1331–6.CrossRef
15.
go back to reference Gamel J, Meyer J, Feuer E, Ba M. The impact of stage and histology on the long-term clinical course of 163,808 patients with breast carcinoma. Cancer. 1996;77:1459–64.CrossRef Gamel J, Meyer J, Feuer E, Ba M. The impact of stage and histology on the long-term clinical course of 163,808 patients with breast carcinoma. Cancer. 1996;77:1459–64.CrossRef
16.
go back to reference Janssen-Heijnen MLG, van Steenbergen LN, Voogd AC, Tjan-Heijnen VCG, Nijhuis PH, Poortmans PM, et al. Small but significant excess mortality compared with the general population for long-term survivors of breast cancer in the Netherlands. Ann Oncol. 2014;25:64–8.CrossRef Janssen-Heijnen MLG, van Steenbergen LN, Voogd AC, Tjan-Heijnen VCG, Nijhuis PH, Poortmans PM, et al. Small but significant excess mortality compared with the general population for long-term survivors of breast cancer in the Netherlands. Ann Oncol. 2014;25:64–8.CrossRef
17.
go back to reference Bouillon K, Haddy N, Delaloge S, Garbay J-R, Garsi J-P, Brindel P, et al. Long-term cardiovascular mortality after radiotherapy for breast cancer. J Am Coll Cardiol. 2011;57:445–52.CrossRef Bouillon K, Haddy N, Delaloge S, Garbay J-R, Garsi J-P, Brindel P, et al. Long-term cardiovascular mortality after radiotherapy for breast cancer. J Am Coll Cardiol. 2011;57:445–52.CrossRef
18.
go back to reference Dal Maso L, Guzzinati S, Buzzoni C, Capocaccia R, Serraino D, Caldarella A, et al. Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818,902 Italian patients and 26 cancer types. Ann Oncol. 2014;25(11):2251–60.CrossRef Dal Maso L, Guzzinati S, Buzzoni C, Capocaccia R, Serraino D, Caldarella A, et al. Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818,902 Italian patients and 26 cancer types. Ann Oncol. 2014;25(11):2251–60.CrossRef
20.
go back to reference Fleming ID, Cooper JS, Henson DE, et al., editors. AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven; 1997. Fleming ID, Cooper JS, Henson DE, et al., editors. AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven; 1997.
21.
go back to reference Cronin KA, Feuer EJ. Cumulative cause-specific mortality for cancer patients in the presence of other causes: a crude analogue of relative survival. Stat Med. 2000;19:1729–40.CrossRef Cronin KA, Feuer EJ. Cumulative cause-specific mortality for cancer patients in the presence of other causes: a crude analogue of relative survival. Stat Med. 2000;19:1729–40.CrossRef
22.
go back to reference Pohar Perme M, Estève J, Rachet B. Analysing population-based cancer survival—settling the controversies. BMC Cancer. 2016;16:933.CrossRef Pohar Perme M, Estève J, Rachet B. Analysing population-based cancer survival—settling the controversies. BMC Cancer. 2016;16:933.CrossRef
24.
go back to reference Feinstein A, Sosin D, Wells C. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312:1604–8.CrossRef Feinstein A, Sosin D, Wells C. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312:1604–8.CrossRef
25.
go back to reference Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin. 2006;56:37–47.CrossRef Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin. 2006;56:37–47.CrossRef
26.
go back to reference Olivotto IA, Chua B, Allan SJ, Speers CH, Chia S, Ragaz J. Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancer. J Clin Oncol. 2003;21(5):851–4.CrossRef Olivotto IA, Chua B, Allan SJ, Speers CH, Chia S, Ragaz J. Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancer. J Clin Oncol. 2003;21(5):851–4.CrossRef
27.
go back to reference Woods LM, Morris M, Rachet B. No, “cure” within 12 years of diagnosis among breast cancer patients who are diagnosed via mammographic screening: women diagnosed in the West Midlands region of England 1989–2011. Ann Oncol. 2016;27:2025–31.CrossRef Woods LM, Morris M, Rachet B. No, “cure” within 12 years of diagnosis among breast cancer patients who are diagnosed via mammographic screening: women diagnosed in the West Midlands region of England 1989–2011. Ann Oncol. 2016;27:2025–31.CrossRef
28.
go back to reference Clèries R, Rooney RM, Vilardell M, Espinàs JA, Dyba T, Borras JM. Assessing predicted age-specific breast cancer mortality rates in 27 European countries by 2020. Clin Transl Oncol. 2018;20(3):313–21. Clèries R, Rooney RM, Vilardell M, Espinàs JA, Dyba T, Borras JM. Assessing predicted age-specific breast cancer mortality rates in 27 European countries by 2020. Clin Transl Oncol. 2018;20(3):313–21.
29.
go back to reference Kramer BS, Welch HG, Prorok PC, O’Malley AJ, Kramer BS. Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. N Engl J Med. 2016;375:1438–47.CrossRef Kramer BS, Welch HG, Prorok PC, O’Malley AJ, Kramer BS. Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. N Engl J Med. 2016;375:1438–47.CrossRef
30.
go back to reference Martinez-Alonso M, Vilaprinyo E, Marcos-Gragera R, Rue M. Breast cancer incidence and overdiagnosis in Catalonia (Spain). Breast Cancer Res. 2010;12(4):R58.CrossRef Martinez-Alonso M, Vilaprinyo E, Marcos-Gragera R, Rue M. Breast cancer incidence and overdiagnosis in Catalonia (Spain). Breast Cancer Res. 2010;12(4):R58.CrossRef
31.
go back to reference Duffy SW, Etzioni R, Sasieni P. Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality. Evid Based Med. 2017;22:76.CrossRef Duffy SW, Etzioni R, Sasieni P. Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality. Evid Based Med. 2017;22:76.CrossRef
32.
go back to reference Puig-Vives M, Sánchez MJ, Sánchez-Cantalejo J, Torrella-Ramos A, Martos C, Ardanaz E, et al. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study. Gynecol Oncol. 2013;130:609–14.CrossRef Puig-Vives M, Sánchez MJ, Sánchez-Cantalejo J, Torrella-Ramos A, Martos C, Ardanaz E, et al. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study. Gynecol Oncol. 2013;130:609–14.CrossRef
Metadata
Title
Long-term crude probabilities of death among breast cancer patients by age and stage: a population-based survival study in Northeastern Spain (Girona–Tarragona 1985–2004)
Authors
R. Clèries
A. Ameijide
M. Buxó
J. M. Martínez
R. Marcos-Gragera
M.-L. Vilardell
M. Carulla
Y. Yasui
M. Vilardell
J. A. Espinàs
J. M. Borràs
J. Galceran
À. Izquierdo
Publication date
01-10-2018
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 10/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-1852-1

Other articles of this Issue 10/2018

Clinical and Translational Oncology 10/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine